Advertisements

Cafeine Sterop

Quick links to important sections

Cafeine Sterop

Advertisements

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Cafeine Sterop

Property Description
Active ingredient Caffeine (INN)
Form Solution injectable / Concentrate for infusion
Pharmacological class Central Nervous System (CNS) stimulant; Methylxanthine derivative
General Purpose Supports regulation of vital, spontaneous functions
Origin Synthetic organic compound

Cafeine Sterop is a medicinal product containing highly purified Caffeine as its sole active ingredient (INN), chemically identified as 1,3,7-trimethylxanthine. It is classified as a Central Nervous System (CNS) stimulant, belonging to the methylxanthine derivative pharmacological class. This classification is clinically recognized for compounds that modulate CNS activity. The product, manufactured by Laboratoires Sterop SA-NV, utilizes a precision-manufactured, synthetic form of the compound, ensuring pharmaceutical quality and batch-to-batch consistency required for critical care settings.

Composition, Form, and Route of Administration

The medicine is a single active ingredient product, formulated as a sterile, clear aqueous solution intended for immediate clinical application. Cafeine Sterop is specifically presented as a Solution injectable or a Concentrate for solution for infusion. This specialized parenteral presentation, intended for intravenous (IV) administration, is a key distinguishing factor, setting it apart from common oral preparations. The formulation bypasses the digestive system to guarantee complete bioavailability and a rapid onset of action, which is paramount in acute or supportive care scenarios.

General Purpose and Fundamental Action

The medicine's core therapeutic principle is its action as an adenosine receptor antagonist. Caffeine achieves its effect by blocking the binding of adenosine, a neuromodulator that reduces nerve activity, thereby promoting increased neurological and respiratory drive. This generalized CNS stimulation is the foundation for the drug's overarching purpose: to support and stabilize crucial, spontaneous functions, often used in supportive care aimed at regulating consistent respiratory patterns.

Regulatory References

  1. Pharmacology of Caffeine
Advertisements

What side effects are possible with Cafeine Sterop?

Possible side effects and safety information

The safety profile for this medication is organized according to the frequency and system-organ-class groupings documented in official regulatory labeling. These classifications communicate the range of documented adverse effects.

Official Adverse Reaction Categories

Adverse effects are categorized based on their documented frequency in clinical studies:

  • Very Common (Affects 1 in 10 or more): Increased urine output and constipation are the most frequently documented adverse reactions.
  • Common (Affects up to 1 in 10): Effects documented in this category include changes in heart rate (Tachycardia), metabolic disturbances such as Hyperglycaemia and Acidosis, and serious conditions like Sepsis and Cerebral haemorrhage.
  • Uncommon (Affects up to 1 in 100): Less frequent but documented events include Arrhythmia and Convulsions/Seizures.

Adverse reactions are further grouped by the physiological system affected, including Cardiac disorders, Gastrointestinal disorders (e.g., Necrotising Enterocolitis), Nervous system disorders, and Metabolism and nutrition disorders.

Serious Safety Considerations

The official safety information highlights reactions of clinical significance. Necrotising Enterocolitis is noted as a serious adverse reaction associated with methylxanthine use. Additionally, the label documents the potential for Convulsions/Seizures, particularly in the context of drug accumulation.

Population-Specific Safety Notes

The regulatory profile mandates caution in certain patient groups due to the risk of drug accumulation. Individuals with hepatic or renal impairment may experience a prolonged drug half-life, which increases the potential for adverse effects. Safety restrictions also include a Contraindication for individuals with known hypersensitivity to the drug substance.

Advertisements

Overdose and Emergency Response

The official regulatory documentation describes overdose of this injectable formulation as manifesting primarily through severe Central Nervous System (CNS) hyper-stimulation. Documented peripheral signs include tremors, restlessness, agitation, and diuresis (increased urine output). Cardiovascular manifestations, such as tachycardia (rapid heart rate) and cardiac arrhythmia (irregular heart rhythm), are also reported in the labeling. Other clinical findings include vomiting and evidence of metabolic effects like hyperglycemia.

Overdose represents a serious toxicity risk, particularly when plasma caffeine concentrations exceed 50 mg/L, a threshold associated with severe outcomes. The most critical documented manifestations in regulatory reports include seizures and potentially life-threatening cardiac irregularities.

Immediate medical attention is required for any suspected overdose. Caregivers must consult a physician urgently if specific symptoms are observed, such as signs of significant gastrointestinal intolerance or unexplained lethargy. The treatment approach mandated by regulatory authorities is entirely symptomatic and supportive, as no specific antidote is known. Management measures officially described include the use of intravenous sedatives to manage CNS excitation and continuous cardiorespiratory monitoring. The official label specifically notes that patients with impaired renal or hepatic function face a heightened risk of toxic accumulation.

Advertisements

Therapeutic Uses of Cafeine Sterop

Cafeine Sterop is relevant for use in critical and specialized clinical settings where patients require assistance with spontaneous functions. Its uses center on addressing specific symptom clusters driven by central nervous system instability or vascular dysregulation.


Support for Immature Respiratory Function in Preterm Infants

This medication is commonly used to help with Central Respiratory Irregularity, which encompasses the recurrent cessation of breathing (apnea of prematurity) and episodes of intermittent low blood oxygen saturation (SpO2) often seen in preterm infants. The medication is relevant for use in primary apnoea of premature newborns, where it is applied during a critical developmental phase to help the patient maintain a consistent and stable breathing pattern. This supportive relief provides support that contributes to easing the overall symptom load and may assist with neurodevelopmental stability in this vulnerable group.

Common uses for supportive management include apnea of prematurity, facilitating ventilator transition, and acute post-dural puncture headache relief.

Acute Relief of Procedure-Related Severe Headache

In a different clinical domain, this medication may be used to provide symptomatic relief for a specific, severe type of headache known as post-dural puncture headache. This acute manifestation often occurs following certain spinal procedures. The medication offers short-term symptomatic assistance to ease this intense, positionally-dependent discomfort, which supports general well-being during symptomatic phases.


Conditions Related to Severe Headache Management

Cafeine Sterop may be part of symptomatic management for post-dural puncture headache—a condition characterized by heightened pain and discomfort that interferes with daily functioning following certain medical procedures.

Advertisements

Eligibility and Restrictions for Use

The official regulatory eligibility for the injectable formulation of this medicine is defined narrowly, focusing on a specific patient population in a specialized care setting.

Populations Allowed and Contraindicated

Classification Eligibility Status (Official Labeling)
Eligible Population Premature newborn infants receiving treatment for primary apnoea of prematurity, a condition related to the baby's underdeveloped breathing centers.
Contraindication Patients who have demonstrated hypersensitivity (severe allergy) to caffeine citrate or to any of the product’s non-medicinal components.
Ineligible Groups The medicine is not indicated for use in adults, older children, adolescents, or any patient population outside of premature newborns.

Conditional Use and Restrictions

Regulatory documents mandate that the medicine be used with caution in infants with certain coexisting medical issues due to the potential for accumulation or worsening of the condition:

  • Impaired Organ Function: Caution is required in infants with impaired renal function (kidney disease) or impaired hepatic function (liver disease), often requiring monitoring of plasma concentrations.
  • Comorbid Conditions: Caution is advised in newborns with seizure disorders or known cardiovascular disease.

Treatment should only be initiated after other causes of apnoea, such as sepsis or central nervous system disorders, have been ruled out or appropriately treated. Furthermore, mothers who are breastfeeding a treated infant must not ingest caffeine-containing products to avoid increasing the infant's plasma caffeine levels.

Advertisements

What should I know about interactions with other medicines?

The official regulatory profile for Cafeine Sterop interactions is structured around the substance's primary metabolic pathway and its intrinsic pharmacological class. The active ingredient, Caffeine, is almost exclusively eliminated via the hepatic enzyme Cytochrome P450 1A2 (CYP1A2). Consequently, co-administration with medicines or substances that inhibit this enzyme may lead to a decrease in systemic clearance and resulting elevated plasma concentrations of caffeine.

An interaction with other methylxanthine derivatives, such as Theophylline, is documented to carry a risk of additive CNS effects that may intensify their combined pharmacodynamic properties.

Exposure-Modifying Substances

Interacting Substance/Class Official Interaction Outcome (Effect on Caffeine)
Cimetidine, Disulfiram Decreased clearance, resulting in increased plasma levels.
Oral Contraceptive Steroids Impaired elimination, increasing systemic exposure.
Smoking (Tobacco/Marijuana smoke) Accelerated metabolism via CYP1A2 induction, leading to reduced systemic exposure.

Official restrictions include the limitation or avoidance of caffeine-containing foods and beverages (e.g., cola, chocolate, coffee) to prevent excessive exposure, a caution particularly relevant to the pediatric population. Furthermore, official prescribing information notes that the risk of reduced clearance is magnified in preterm neonates with underlying impaired hepatic or renal function.

Advertisements

Mechanism of Action

How Cafeine Sterop Works: Mechanism of Action

Cafeine Sterop primarily acts as a competitive antagonist at adenosine receptors ( A1 and A2 A), particularly in the central nervous system. By blocking the binding of the inhibitory neuro-mediator adenosine, the drug prevents the suppression of neural firing and promotes the release of excitatory neurotransmitters, notably dopamine and norepinephrine, resulting in enhanced central nervous system (CNS) excitability.

At elevated systemic concentrations, the drug exhibits a secondary mechanism as a non-selective Phosphodiesterase ( PDE) inhibitor. This action reduces the degradation of the intracellular second messenger cyclic AMP ( cAMP), causing its levels to rise. This molecular cascade enhances sympathetic nervous system outflow and contributes to altered cardiovascular dynamics (e.g., increased heart rate and contractility).

Collectively, these mechanisms lead to system-level physiological modulation, including cerebral vasoconstriction and an increase in renal blood flow, which alters fluid balance, characterized by diuresis. The combined central and peripheral actions determine the drug's overall profile of physiological responses.

Advertisements

Dosage and Administration Information

The administration of injectable caffeine is governed by protocols that detail its use in highly specialized settings for specific patient populations. All usage must adhere to the official instructions outlined in prescribing documents.

Administration Scope

Feature Neonatal Apnoea (Caffeine Citrate) Post-Dural Puncture Headache (IV Caffeine Anhydrous)
Route of administration Intravenous (IV) infusion for the initial loading dose; IV infusion or oral for maintenance doses. Intravenous (IV) infusion only.
Dosing schedule Loading Dose: 20 mg/kg Caffeine Citrate. Maintenance Dose: 5 mg/kg/day. Single Dose: Fixed mg dose up to 500 mg.
Preparation requirements (if applicable) May be administered undiluted or diluted in compatible sterile solutions. Dose must be accurately measured. The concentrate formulation requires mandatory dilution in a large volume of solution (e.g., 0.9% sodium chloride) prior to infusion.
Age-group administration rules For premature infants between 28 and <33 weeks gestational age. Dose must be adjusted and monitored in cases of renal or hepatic impairment. For adults and children over 15 years; use is not recommended for younger children in this context.
Special procedural conditions The IV loading dose must be infused slowly over 30 minutes; maintenance over 10 to 15 minutes. Treatment must be initiated in a NICU. The IV infusion must be administered slowly over 1 to 2 hours. A second dose may be administered 4 to 8 hours after the initial dose, if indicated.

Instruction Classifications (High-Level)

  • Administration method type: Parenteral (IV) with limited oral option for maintenance.
  • Frequency pattern: Once daily (neonatal maintenance) or single/as-needed (headache relief).
  • Regulatory basis: Established clinical and pharmaceutical standards.
  • Use-context constraints: Administration is restricted to specialized hospital settings under physician supervision.

Connection to the Overall Use Protocol

The framework establishes precise, weight- or fixed-dose regimens delivered via slow IV infusion, which must be administered in a monitored environment. This structure requires strict adherence to mandatory dilution rules and precise timing protocols to ensure the medicine is used in compliance with official prescribing information.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cafeine Sterop

Evidence for Use in Immature Respiratory Function in Preterm Infants

Research exploring the use of the medicine to address specific breathing irregularities and the need for mechanical ventilation in premature newborns has been conducted through short-term Randomized Controlled Trials (RCTs) and subsequent systematic reviews. These studies monitored outcomes related to functional imbalance, specifically measuring the frequency of temporary cessation of breathing (apnoea) and the timing of transition off mechanical respiratory support (extubation). Findings from large clinical evaluations described patterns observed in the studies, including measurements related to the timing of discontinuing mechanical ventilation. Some trials reported that the administration was associated with a lower measured incidence of Bronchopulmonary Dysplasia (BPD) and a lower measured risk of death or BPD combined.

Long-Term Follow-up Studies and Developmental Outcomes

Long-term follow-up studies, which are extensions of the original short-term RCTs, were applied in studies examining patient experiences and functional scales in children years after their initial treatment. Long-term follow-up reports describe a pattern of measurements related to a lower measured incidence of cerebral palsy in one of the study groups when assessed at two years of corrected age. However, data from older age groups, such as the five-year follow-up, reported that specific functional and cognitive scores appeared to be similar between the groups originally studied.

Evidence for Acute Relief of Procedure-Related Severe Headache

In a different clinical context, the medication was studied for acute symptomatic changes in Post-Dural Puncture Headache (PDPH). Research explored short-term symptom changes in outcomes related to physical discomfort. The findings from these trials were mixed and described patterns related to headache intensity, often monitored using a pain scale in the hours immediately following administration. The evidence for this application is limited, with small sample sizes being common, and the evidence quality varies across studies.

The Landscape of Evidence: Strength, Consistency, and Research Gaps

Overall, the research for Cafeine Sterop demonstrates a varying level of evidence quality and consistency across its studied uses. The evidence base for research exploring immature respiratory function in preterm infants is extensive and consistent. Conversely, the evidence base for research exploring acute symptomatic changes in procedure-related severe headache is limited, with certainty remaining low. Research highlights what is known and what is still uncertain, emphasizing that long-term effects on functional and neurological development beyond early childhood are not fully established, suggesting that research is ongoing to fill these remaining gaps.

Key Studies & References

  1. Postdural Puncture Headache (StatPearls - Treatment Management)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Cafeine Sterop (FAQ)


Q: Can Cafeine Sterop cause headaches or migraines?

A: Official information lists headache as an infrequently reported side effect of caffeine in a general context. While the specific regulatory profile for Cafeine Sterop (caffeine citrate) does not list headache as a very common side effect in the primary patient population, the related drug class is generally associated with symptoms associated with the drug class.


Q: Are there any common foods or drinks that should be avoided when taking Cafeine Sterop?

A: The official product information advises limiting the consumption of foods, beverages, or other medicines that contain caffeine. Examples include drinks such as coffee, tea, and cola. This restriction is advised to help prevent excessive levels of caffeine in the body.


Q: Can the effects of Cafeine Sterop be felt immediately or does it build up over time?

A: This medication is administered via a slow intravenous (IV) infusion, which is done over a set period of time. Due to its long half-life in the eligible patient population, therapeutic levels are sustained over many hours rather than resulting in a momentary effect. It is part of a regimen that includes an initial dose followed by daily maintenance doses.


Q: What are the warning signs listed for an allergic reaction to Cafeine Sterop?

A: Official safety documents list hypersensitivity (severe allergy) to the drug's components as a contraindication, meaning it should not be used. Symptoms that could signal a severe allergic reaction include swelling of the face, lips, or tongue, difficulty breathing, or the appearance of hives. If these signs are observed, contact a healthcare professional immediately.


Q: Does Cafeine Sterop cause changes in appetite?

A: The official label includes reports of 'feeding problems' or 'feeding intolerance' as common side effects in the eligible patient population. This indicates that a lack of desire or a difficulty to feed has been observed.


Q: Is it possible to become dependent on Cafeine Sterop after taking it for a long time?

A: The medication is approved for short-term treatment. Regulatory documents have noted that behavioral changes may be observed upon the withdrawal of caffeine treatment. For this reason, monitoring for apnea recurrence is recommended for approximately one week after treatment cessation.


Q: Does Cafeine Sterop have an official classification, like a controlled substance?

A: The active ingredient in this medicine, caffeine, is officially classified as a non-controlled substance. It does not fall under the scheduling categories set forth by authorities like the U.S. Drug Enforcement Administration (DEA).


Q: Can people taking heart medication also use Cafeine Sterop?

A: Official warnings note that caution and monitoring are required in patients who have known cardiovascular disease. This is due to the potential for the medicine to increase the heart rate (tachycardia) and cause irregular heart rhythms (arrhythmia). Official documents do not provide a blanket statement covering interactions with all specific heart medications.


Q: Is there a maximum amount of time a person is usually advised to take Cafeine Sterop?

A: Official regulatory documents indicate that the safety and effectiveness of the drug for its primary use have only been established for a specific duration, typically stated as 10 to 12 days for short-term treatment.


Q: What happens if a dose of Cafeine Sterop is missed?

A: If a dose is missed, patient-focused regulatory guidance generally advises that it should be given with the next scheduled administration. Regulatory patient guidance specifies that a double dose should not be given to make up for a missed dose.


Q: Is Cafeine Sterop safe to use for teenagers?

A: The primary indication for this injectable medicine is for premature newborn infants. While official documents mention its use for Post-Dural Puncture Headache in adults and children over 15, its indications do not widely endorse general use in the broader adolescent population.


Q: Does Cafeine Sterop interact with common over-the-counter cold medicines?

A: The official label warns about interactions with medicines that affect the CYP1A2 enzyme, which processes the drug. Some common cold medicines may contain stimulants or other ingredients that could intensify the effects of Cafeine Sterop, and this is a circumstance where caution is required.


Q: Are there any known interactions between Cafeine Sterop and herbal supplements?

A: Official patient information indicates that a healthcare professional should be informed about all medicines being taken. This includes all vitamins, minerals, natural health supplements, and herbal remedies, as interactions with these substances may be possible.


Q: Why do official documents mention limiting other sources of caffeine while taking Cafeine Sterop?

A: The official restriction to limit other sources of caffeine is stated to prevent the risk of excessive systemic exposure. This is due to the cumulative and additive pharmacological effects that multiple sources of caffeine could have on the body.


Q: Do older adults typically need a different dosage of Cafeine Sterop?

A: The primary indication is in premature infants, so official regulatory documents do not provide specific information on the relationship between age and the drug's effects in geriatric patients for this specific use. Dosage information focuses on the weight and age of the eligible patient population.


Q: Is Cafeine Sterop available over the counter, or is it prescription-only?

A: This medication is a concentrated, injectable solution that is available by prescription only. Official regulatory documents restrict its administration to specialized hospital settings, under the supervision of a physician.


Q: What happens when the effects of Cafeine Sterop start to wear off?

A: Due to the medicine's long half-life in the target patient population, the effects resolve slowly over a period of time. Because of the risk of the original condition recurring after treatment is stopped, monitoring is typically required for approximately one week after the cessation of the medicine.


Q: Can Cafeine Sterop cause dizziness or lightheadedness?

A: Official safety documents list dizziness and lightheadedness as less common side effects that have been reported for caffeine-containing products. If these symptoms are experienced, official guidance recommends notifying the care team.


Q: Is it common for people to report difficulty sleeping after using Cafeine Sterop?

A: Official patient instructions warn about the possibility of restlessness, jitteriness, or shakiness, which are common effects of CNS stimulants. Insomnia is generally listed as a common side effect for caffeine, though studies in the target patient population have shown no consistent negative impact on key sleep parameters.


Q: Can Cafeine Sterop be crushed or split if swallowing is difficult?

A: The product is formulated as a sterile aqueous solution, specifically for intravenous (IV) injection or oral administration via a feeding tube. It is not manufactured as a solid tablet or capsule that is meant to be crushed or split.


Q: Is there a risk of withdrawal symptoms when stopping Cafeine Sterop?

A: Monitoring is recommended for approximately one week after treatment cessation due to the risk of apnea recurrence, and the regulatory review noted that behavioral changes may be possible upon withdrawal of caffeine treatment.


Q: Are there any specific lifestyle changes recommended when starting Cafeine Sterop?

A: The primary recommended changes focus on limiting outside exposure to substances that could affect the drug. This includes minimizing the intake of other caffeine-containing products (food and beverages) and avoiding smoking or exposure to tobacco smoke.

Advertisements

How should Cafeine Sterop be stored and disposed of?

Official Storage and Disposal Requirements

The storage and disposal instructions for Cafeine Sterop are based strictly on regulatory labeling to ensure product stability and safe handling.

Requirement Official Regulatory Instruction
Storage Temperature Store at or below 25 C (Controlled Room Temperature Range).
Environmental Control Protect from light by storing in the original outer carton. Do not freeze.
Container & Stability The vial is for single use only. Any unused portion remaining must be immediately discarded after a dose is removed.
Child Safety The medicine must be stored out of the sight and reach of children.
Disposal Disposal of unused product or waste material must follow local regulations and should not be discharged into wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cafeine Sterop found in:

A-Z Index: